scholarly journals Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist

2018 ◽  
Vol 22 (11) ◽  
pp. 5367-5377 ◽  
Author(s):  
Chengying Xie ◽  
Huajun Zhao ◽  
Xubin Bao ◽  
Haoyu Fu ◽  
Liguang Lou
Keyword(s):  
Receptor Agonist ◽  
Pharmacological Characterization ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist ◽  
Orally Active

Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist

2011 ◽  
Vol 650 (1) ◽  
pp. 58-63 ◽  
Author(s):  
Masaki Abe ◽  
Ken-ichi Suzuki ◽  
Chinatsu Sakata ◽  
Keizo Sugasawa ◽  
Fukushi Hirayama ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Pharmacological Profile ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist ◽  
Orally Active

Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist

2005 ◽  
Vol 33 (1) ◽  
pp. 85-93 ◽  
Author(s):  
Connie L. Erickson-Miller ◽  
Evelyne DeLorme ◽  
Shin-Shay Tian ◽  
Christopher B. Hopson ◽  
Kenneth Stark ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist

AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist

2009 ◽  
Vol 82 (4) ◽  
pp. 247-254 ◽  
Author(s):  
Mari Fukushima-Shintani ◽  
Ken-ichi Suzuki ◽  
Yoshiyuki Iwatsuki ◽  
Masaki Abe ◽  
Keizo Sugasawa ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist ◽  
Orally Active

Quality of Life Improvements Following Eltrombopag Treatment in Children with Chronic Immune Thrombocytopenia: Case Report

2021 ◽  
Vol 104 (4) ◽  
pp. 672-675
Keyword(s):  
Quality Of Life ◽  
Platelet Count ◽  
Receptor Agonist ◽  
Immune Thrombocytopenia ◽  
Case Series ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist ◽  
Low Platelet Count ◽  
Chronic Immune Thrombocytopenia

The present case series described six chronic immune thrombocytopenia patients (cITP), with a median age of 7.7 (7.0 to 13.0) years and low platelet count at 15,500 (7,000 to 20,000)/uL. They were suffering from bleeding symptoms and side effects of treatment. After enrollment, they were treated with thrombopoietin receptor agonist (eltrombopag). Five patients responded positively, showing a median platelet count of 115,000 (39,000 to 433,000)/uL. The median dose of eltrombopag used was 1.3 (0.8 to 2.2) mg/kg/day. The quality of life (QoL) improved for all patients, with their median overall score using a Pediatric QoL questionnaire showing 25.0% improvement. Median scores also showed improvements in each sphere of life functioning as physical (30.8%), emotional (26.4%), social (16.4%), and school (21.4%). The present report demonstrated that a select group of cITP patients, with low platelet count and bleeding symptoms, benefitted from treatment with eltrombopag, as shown by increased platelet counts and improved QoL. Keywords: Chronic ITP, Thrombopoietin receptor agonist, Children

CP-080 Thrombopoietin receptor agonist treatment in idiopathic thrombocytopenic purpura

2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A32.1-A32
Author(s):  
MH García Lagunar ◽  
I Español Morales ◽  
M Martínez Penella ◽  
I Muñoz García ◽  
M Gutiérrez Cívicos ◽  
...  
Keyword(s):  
Idiopathic Thrombocytopenic Purpura ◽  
Receptor Agonist ◽  
Thrombocytopenic Purpura ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist
Sign in / Sign up

Export Citation Format

Share Document